Alembic Pharmaceuticals has released a revised investors presentation regarding its unaudited financial results for the third quarter (Q3) and the nine months ended December 31, 2025. The presentation provides key financial highlights and a business performance overview, encompassing its India Branded Business, US Generics, Ex-US Generics, and API segments. The company requests stakeholders to review the provided information.
Q3 FY26 Performance Highlights
Alembic Pharmaceuticals has announced the release of its revised investor presentation, detailing the company’s unaudited financial outcomes for the quarter and nine months ending December 31, 2025.
Financial Snapshot
Key figures for Q3 FY26 include:
- Revenue: INR 18.76 Bn (up 11% YoY)
- EBIDTA: INR 3.08 Bn (up 14% YoY), with an EBIDTA Margin of approximately 16%
- R&D Expenditure: 9% of revenue (up 33% YoY)
- Net Profit Before Tax: INR 2.04 Bn, resulting in a Net Profit Margin of 11%
Segment Performance
India Branded Business
Achieved a 6% YoY growth with revenues of INR 6.52 billion.
US Generics
Reported a 6% YoY increase, driven by new product launches and market share gains.
Ex-US Generics
Reached an all-time high in revenue, delivering 36% YoY growth.
API Business
Reported stable growth of 2%.
Animal Health Business
The Animal Health division recorded 22% growth in the quarter.
R&D and Approvals
The company has a total of 232 approved ANDAs, which includes 20 tentative approvals.
Sustainability Initiatives
Alembic is committed to several sustainability targets, including Net Zero by 2050 and Water Neutrality by 2027. The company is focused on reducing GHG emissions and improving its environmental footprint.
Source: BSE
